{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:43:34Z","timestamp":1782938614660,"version":"3.54.5"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,10]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>With the popularity of ICIs in different oncology treatments, immune-related adverse events have raised concerns, mostly occurring in skin and endocrine gland injury. This disease involves different organ systems and presents with a variety of clinical manifestations. Most patients with immune checkpoint inhibitor-induced type 1 diabetes are reported to have no combination of autoimmune disease. We report a case of Sintilimab-related diabetes mellitus and psoriasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a case of a 65-year-old female with Sintilimab-related diabetes mellitus and psoriasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient treated with anti-programmed cell death protein 1 (Sintilimab) for 4 cycles. The patient presented with inexplicable bouts of nausea and vomiting, accompanied by chest discomfort and a feeling of breathlessness, prompting their admission to the local hospital. The initial assessment upon admission revealed an abrupt elevation in blood glucose levels, alongside normal ketone levels, lactic acidosis, and hyperuricemia. A comprehensive regimen was provided to regulate glucose levels and address the symptoms, resulting in notable improvement and subsequent discharge. Regrettably, the patient\u2019s personal decision to discontinue medication for a single day led to the emergence of acute ketoacidosis, coupled with a recurrence of psoriasis vulgaris. Consequently, readmission became necessary. Based on the patient\u2019s medical history and diabetes antibody testing, the diagnosis of immune checkpoint inhibitor induced diabetes mellitus has been confidently established.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient ceased treatment with Sintilimab and was initiated on insulin therapy for glycemic control, alongside symptomatic management for psoriasis. Upon stabilization of the condition, long-term administration of exogenous insulin was implemented as a substitute treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcome:<\/jats:title>\n            <jats:p>Outside of the hospital, insulin therapy effectively maintained stable blood glucose levels, and there were no further episodes of psoriasis flare-ups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lesson:<\/jats:title>\n            <jats:p>The clinical manifestations of immune checkpoint inhibitor induced diabetes mellitus are variable, and in this case the patient presented with unique primary symptoms. Therefore, it is crucial to accumulate relevant cases, understand the different clinical presentations and identify the underlying mechanisms of the disease. This will provide further evidence for early therapeutic intervention in similar patients in the future.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000035946","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T19:16:14Z","timestamp":1699643774000},"page":"e35946","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7468-2129","authenticated-orcid":false,"given":"Wenying","family":"Huang","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, Weifang Medical University, Affiliated Hospital of Weifang Medical University, Weifang, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Weifang Medical University, Affiliated Hospital of Weifang Medical University, Weifang, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Weifang Medical University, Affiliated Hospital of Weifang Medical University, Weifang, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xue","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Weifang Medical University, Affiliated Hospital of Weifang Medical University, Weifang, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichao","family":"Bao","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Weifang Medical University, Affiliated Hospital of Weifang Medical University, Weifang, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Weifang Medical University, Affiliated Hospital of Weifang Medical University, Weifang, Shandong Province, China"},{"name":"Department of Endocrinology and Metabolic Diseases, Affiliated Hospital of Weifang Medical University, Weifang, Shandong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"3","article-title":"A case of psoriasis induced by immune checkpoint inhibitor pablizumab and review of the literature.","volume":"37","author":"He","year":"2021","journal-title":"Chin J Lepr Skin Dis"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","article-title":"Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy.","volume":"10","author":"Baden","year":"2019","journal-title":"Diabetol Int"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors.","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor-associated diabetes.","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","article-title":"Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report.","volume":"64","author":"Martin-Liberal","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00592-019-01402-w","article-title":"The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: proposed algorithms for management.","volume":"25","author":"Del Rivero","year":"2020","journal-title":"Oncologist"},{"key":"R8-20250504","first-page":"649","article-title":"Clinical diagnosis and treatment of immune-related adverse events of endocrine system related to immune checkpoint inhibitors.","volume":"22","author":"Duan","year":"2019","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance.","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"R10-20250504","first-page":"1","article-title":"Immune checkpoint molecules and tumor immunotherapy\u2014interpreting the 2018 Nobel prize in physiology or medicine.","volume":"53","author":"Zhang","year":"2018","journal-title":"Biol Bull"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3390\/cancers12082314","article-title":"Endocrine adverse events of nivolumab in non-small cell lung cancer patients-literature review.","volume":"12","author":"Dudzinska","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R12-20250504","first-page":"639","article-title":"Management of dermatologic toxicities related to immune checkpoint inhibitors.","volume":"22","author":"Si","year":"2019","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy.","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"R14-20250504","first-page":"667","article-title":"Guideline for the diagnosis and treatment of psoriasis in China (2018 complete edition).","volume":"52","year":"2019","journal-title":"Chin J Dermatol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2326-6066.CIR-18-0682","article-title":"IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy.","volume":"7","author":"Johnson","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","article-title":"Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).","volume":"42","author":"Ruggeri","year":"2019","journal-title":"J Endocrinol Invest"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:29:50Z","timestamp":1746325790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":18,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035946","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}